Trial experts join FierceBiotech webinar panel

We've lined up two more clinical trial experts to offer you some fresh insights into more efficient trial designs for our webinar on December 15th at 2 p.m. EST. Dr. Royce Morrison, director of clinical strategy for Charles River Clinical Services, and Dr. Barbara Tardiff, corporate vice president of data sciences at Parexel, will be joining Tufts' Ken Getz and expert developer Neil Bodick.

Morrison has played an instrumental role in developing Charles River's specialized Phase I capabilities, including cardiac safety and radiolabeled studies, and case-specific designs of first-in-human protocols. And Dr. Tardiff has helmed the expansion of Parexel's data services--including data management, biostatistics and related applications of information technology.

Bodick, of course, is well known for his research work at Eli Lilly's Chorus, which helped shave time and money from the pharma company's clinical trial work. He's now using that experience to advance new drug programs planned at Flexion. And Getz tells me that he will focus on some of the recent work he's been doing on trial design. All four of our experts will be on hand to offer some practical advice on how you can better manage your development budget while improving your odds for an approval--or a deal.

As usual, we'll be offering our audience an opportunity to pose questions to the panelists following their presentations. And you can expect an engaging exchange about the new technology and ideas that are reshaping the way biotech companies develop innovative therapies. The 'early bird' rate ends on Thursday. Click here to register. -- John Carroll

Suggested Articles

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.